Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ABO is a modulator of annexin A7.1 It binds to Thr286 and inhibits phosphorylation of annexin A7 at threonine, but not serine or tyrosine, residues in human umbilical vein endothelial cells (HUVECs). ABO enhances the interaction between annexin A7 and the EF-hand protein GCA, decreases GCA phosphorylation as well as intracellular calcium concentration, and promotes autophagy in COS-7 cells. It also decreases phosphorylation of microtubule-associated protein 1 light chain (LC3) in HUVECs and suppresses oxidized low-density lipoprotein-induced increases in phosphatidylcholine-specific phospholipase C (PC-PLC) expression in vascular endothelial cells (VECs).1,2 In vivo, ABO (50 or 100 mg/kg per day) decreases PC-PLC levels, enhances autophagy, and reduces apoptosis, lipid deposition, and atherosclerotic plaque area in the aortic endothelium of apoE-/- mice fed a Western diet.2
WARNING This product is not for human or veterinary use.
1. Identification of a small molecule targeting annexin A7. Biochim. Biophys. Acta 1883(9), 2092-2099 (2013).
2. Targeting annexin A7 by a small molecule suppressed the activity of phosphatidylcholine-